JAZZ LongStrong financials and earnings growth appears to have bottomed out and is now on the trend up. Healthcare can also be a hedge against inflation, which has a serious chance of reemerging, especially if rates were to pause.
15,488.000
0.003 BRL
2.07 B BRL
19.15 B BRL
About Jazz Pharmaceuticals plc
Sector
CEO
Bruce C. Cozadd
Headquarters
Dublin
Website
Founded
2005
ISIN
BRJ2AZBDR009
FIGI
BBG014XJG8K5
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Displays a symbol's price movements over previous years to identify recurring trends.
J
JAZZ5172103
Jazz Securities Designated Activity Company 4.375% 15-JAN-2029Yield to maturity
5.94%
Maturity date
Jan 15, 2029
Explore more bonds